| Code | CSB-RA013047MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to ABBV-141, targeting lysophosphatidic acid receptor 1 (LPAR1), also known as LPA1 or EDG2. LPAR1 is a G protein-coupled receptor that mediates cellular responses to lysophosphatidic acid (LPA), a bioactive lipid involved in diverse physiological processes including cell proliferation, migration, survival, and cytoskeletal remodeling. LPAR1 signaling plays critical roles in nervous system development, vascular integrity, and wound healing. Aberrant LPAR1 activity has been implicated in various pathological conditions, including fibrotic diseases such as idiopathic pulmonary fibrosis and systemic sclerosis, as well as cancer progression, metastasis, and neuropathic pain.
ABBV-141 is a clinical-stage therapeutic antibody originally developed for the treatment of fibrotic diseases by blocking LPAR1-mediated signaling pathways. This biosimilar antibody serves as a valuable research tool for investigating LPAR1 biology, exploring LPA-dependent signaling mechanisms, and studying the therapeutic potential of LPAR1 inhibition in disease models. It enables researchers to examine the role of LPAR1 in fibrosis, oncology, and neurological research contexts.
There are currently no reviews for this product.